GlaxoSmithKline antibiotic goes to FDA review
December 21st, 2007 Posted by: Dr. Cox
The US Food and Drug Administration (FDA) has begun its review of GlaxoSmithKline’s (GSK) investigational antibacterial retapamulin. GSK submitted a new drug application (NDA) for retapamulin in November last year and expects to receive approval later this year.
Retapamulin was developed as a treatment for skin and skin structure infections due to susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. A GSK spokesman explained the importance of the new antibiotic.
He said: “Continued widespread use of antibiotics has promoted the spread of antibiotic resistance and has created an urgent need for antibacterial agents with no known cross-resistance.” It was explained that retapamulin, the first in a new class of antibiotics called pleuromutilins, is unique in how it works by binding to a particular site of a bacteria and it has so far shown no target-specific cross-resistance to other established classes of antibiotics. The NDA is based on clinical trials of over 700 US patients.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.